Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Impedance Device to Prevent Heart Failure Readmission
NCT04080388Phase 3Unknown
- Sponsor
- Hillel Yaffe Medical Center
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute heart failure (AHF), sponsored by Hillel Yaffe Medical Center. Primary endpoint: Prevention of heart failure re-admission at 30 days. Status: unknown.
02
Conditions
acute heart failure (AHF)
Beyond the preview
Go deeper on NCT04080388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080388.